RE:RE:RE:RE:RE:RE:RE:RE:8 of the last 9 months bearishGetting 5% of the SGLT2 class (not the overall oral diabetic market) in China for a meetoo like this without compelling CV safety or endpoint data would be exceptional. The market is changing rapidly, even for China. Lots of new therapies with exceptional characteristics are coming. Maybe licensing it to a NA pharma a few years from now when Jardiance, Invokana, oral GLP1’s etc etc go generic and not promoted anymore would allow the disproportionate share of voice of Sirona little SGLT2 to generate a similar 5% SGLT2 market share after 4 years post launch this side of the pacific in 2026. Howie is too slow to close and the company he chose is too slow to market. Still, despite all that.. a meetoo SGLT2 is worth a current dime a share